Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Subjects
2.2. Laboratory Measurements
2.3. Definition of Diabetes and Diabetes Complications
2.4. Covariates
2.5. Statistical Analyses
3. Results
3.1. Participant Characteristics
3.2. Association Between 4-Hydroxyproline and Diabetes
3.3. Stratified Analyses and Sensitivity Analyses
4. Discussion
4.1. Principal Findings
4.2. 4-Hydroxyproline and Diabetes
4.3. Possible Mechanisms
4.4. Strengths and Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- GBD 2021 Diabetes Collaborators. Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234. [Google Scholar] [CrossRef]
- Xu, Y.; Lu, J.; Li, M.; Wang, T.; Wang, K.; Cao, Q.; Ding, Y.; Xiang, Y.; Wang, S.; Yang, Q.; et al. Diabetes in China Part 2: Prevention, Challenges, and Progress. Lancet Public Health 2024, 9, e1098–e1104. [Google Scholar] [CrossRef] [PubMed]
- Zhao, X.; Zhang, Y.; Yang, Y.; Pan, J. Diabetes-Related Avoidable Hospitalisations and Its Relationship with Primary Healthcare Resourcing in China: A Cross-Sectional Study from Sichuan Province. Health Soc. Care Community 2022, 30, e1143–e1156. [Google Scholar] [CrossRef] [PubMed]
- Xu, Y.; Lu, J.; Li, M.; Wang, T.; Wang, K.; Cao, Q.; Ding, Y.; Xiang, Y.; Wang, S.; Yang, Q.; et al. Diabetes in China Part 1: Epidemiology and Risk Factors. Lancet Public Health 2024, 9, e1089–e1097. [Google Scholar] [CrossRef] [PubMed]
- Srivastava, A.K.; Khare, P.; Nagar, H.K.; Raghuwanshi, N.; Srivastava, R. Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases. Curr. Protein Pept. Sci. 2016, 17, 596–602. [Google Scholar] [CrossRef] [PubMed]
- Shoulders, M.D.; Kotch, F.W.; Choudhary, A.; Guzei, I.A.; Raines, R.T. The Aberrance of the 4S Diastereomer of 4-Hydroxyproline. J. Am. Chem. Soc. 2010, 132, 10857–10865. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Wu, Z.; Hou, Y.; Dai, Z.; Hu, C.-A.A.; Wu, G. Metabolism, Nutrition, and Redox Signaling of Hydroxyproline. Antioxid. Redox Signal. 2019, 30, 674–682. [Google Scholar] [CrossRef] [PubMed]
- Cooper, S.K.; Pandhare, J.; Donald, S.P.; Phang, J.M. A Novel Function for Hydroxyproline Oxidase in Apoptosis through Generation of Reactive Oxygen Species. J. Biol. Chem. 2008, 283, 10485–10492. [Google Scholar] [CrossRef] [PubMed]
- Wu, G. Important Roles of Dietary Taurine, Creatine, Carnosine, Anserine and 4-Hydroxyproline in Human Nutrition and Health. Amino Acids 2020, 52, 329–360. [Google Scholar] [CrossRef] [PubMed]
- Alamshah, S.M.; Hemmati, A.; Nazari, Z. Assessment of Hydroxyproline Levels in Non-Ischemic Diabetic Foot Ulcers During Recovery. A Prospective Case-Control Study. Rom. J. Diabetes Nutr. Metab. Dis. 2015, 22, 361–366. [Google Scholar] [CrossRef]
- Yang, J.; Le, Y.; Wei, T.; Wang, K.; Yang, K.; Xiao, W.; Hong, T.; Wei, R. Non-Targeted Metabolomic Analysis Predicts the Therapeutic Effects of Exenatide on Endothelial Injury in Patients with Type 2 Diabetes. J. Diabetes Its Complicat. 2021, 35, 107797. [Google Scholar] [CrossRef] [PubMed]
- Vidhya, S.; Ramya, R.; Coral, K.; Sulochana, K.N.; Bharathidevi, S.R. Free Amino Acids Hydroxyproline, Lysine, and Glycine Promote Differentiation of Retinal Pericytes to Adipocytes: A Protective Role against Proliferative Diabetic Retinopathy. Exp. Eye Res. 2018, 173, 179–187. [Google Scholar] [CrossRef] [PubMed]
- Quan, W.; Jiao, Y.; Xue, C.; Li, Y.; Liu, G.; He, Z.; Qin, F.; Zeng, M.; Chen, J. The Effect of Exogenous Free Nε-(Carboxymethyl)Lysine on Diabetic-Model Goto-Kakizaki Rats: Metabolomics Analysis in Serum and Urine. J. Agric. Food Chem. 2021, 69, 783–793. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Liu, D.; Ma, Z.; Wang, C.; Gu, S.; Zhou, Z.; Zuo, H. Plasma β-Alanine Is Positively Associated with Risk of Ischemic Stroke: A Nested Case-Control Study. J. Nutr. 2023, 153, 1162–1169. [Google Scholar] [CrossRef] [PubMed]
- Liu, D.; Gu, S.; Zhou, Z.; Ma, Z.; Zuo, H. Associations of Plasma TMAO and Its Precursors with Stroke Risk in the General Population: A Nested Case-control Study. J. Intern. Med. 2023, 293, 110–120. [Google Scholar] [CrossRef] [PubMed]
- Mu, Y.; Gu, Z.; Wang, Q.; Wang, X.; Zhu, J.; Huang, J.; Huang, Q.; Zuo, H. Plasma Kynurenine Pathway Metabolites in Association with Diabetes: A Cross-Sectional Study. Clin. Nutr. 2025, 51, 342–348. [Google Scholar] [CrossRef] [PubMed]
- Pottel, H.; Björk, J.; Courbebaisse, M.; Couzi, L.; Ebert, N.; Eriksen, B.O.; Dalton, R.N.; Dubourg, L.; Gaillard, F.; Garrouste, C.; et al. Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate: A Cross-Sectional Analysis of Pooled Data. Ann. Intern. Med. 2021, 174, 183–191. [Google Scholar] [CrossRef] [PubMed]
- Zuo, H.; Tell, G.S.; Ueland, P.M.; Nygård, O.; Vollset, S.E.; Midttun, Ø.; Meyer, K.; Ulvik, A. The PAr Index, an Indicator Reflecting Altered Vitamin B-6 Homeostasis, Is Associated with Long-Term Risk of Stroke in the General Population: The Hordaland Health Study (HUSK). Am. J. Clin. Nutr. 2018, 107, 105–112. [Google Scholar] [CrossRef] [PubMed]
- Tsai, M.-K.; Gao, W.; Wen, C.-P. The Relationship between Alcohol Consumption and Health: J-Shaped or Less Is More? BMC Med. 2023, 21, 228. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, H.; Jinzu, H.; Nagao, K.; Noguchi, Y.; Shimba, N.; Miyano, H.; Watanabe, T.; Iseki, K. Plasma Amino Acid Profiles Are Associated with Insulin, C-Peptide and Adiponectin Levels in Type 2 Diabetic Patients. Nutr. Diabetes 2014, 4, e133. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.J.; Kwak, S.-Y.; Jo, G.; Song, T.-J.; Shin, M.-J. Serum Metabolite Profile Associated with Incident Type 2 Diabetes in Koreans: Findings from the Korean Genome and Epidemiology Study. Sci. Rep. 2018, 8, 8207. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Wang, N.; Dong, X.; Zhu, J.; Chen, Y.; Jiang, Q.; Fu, C. Associations between Serum Amino Acids and Incident Type 2 Diabetes in Chinese Rural Adults. Nutr. Metab. Cardiovasc. Dis. 2021, 31, 2416–2425. [Google Scholar] [CrossRef] [PubMed]
- Kenéz, Á.; Warnken, T.; Feige, K.; Huber, K. Lower Plasma Trans-4-Hydroxyproline and Methionine Sulfoxide Levels Are Associated with Insulin Dysregulation in Horses. BMC Vet. Res. 2018, 14, 146. [Google Scholar] [CrossRef] [PubMed]
- Peddinti, G.; Cobb, J.; Yengo, L.; Froguel, P.; Kravić, J.; Balkau, B.; Tuomi, T.; Aittokallio, T.; Groop, L. Early Metabolic Markers Identify Potential Targets for the Prevention of Type 2 Diabetes. Diabetologia 2017, 60, 1740–1750. [Google Scholar] [CrossRef] [PubMed]
- Xue, Y.; Cui, A.; Wei, S.; Ma, F.; Liu, Z.; Fang, X.; Huo, S.; Sun, X.; Li, W.; Hu, Z.; et al. Proline Hydroxylation of CREB-Regulated Transcriptional Coactivator 2 Controls Hepatic Glucose Metabolism. Proc. Natl. Acad. Sci. USA 2023, 120, e2219419120. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Shi, B.; Zhang, J.; Ran, L.; Bian, W.; Zhu, Y.; Zhang, K.; Vincent, L. Expression of Transforming Growth Factor β1 Gene, Basic Fibroblast Growth Factor Gene and Hydroxyproline in Diabetes-induced Bladder Dysfunction in a Rat Model. Neurourol. Urodyn. 2008, 27, 254–259. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Chai, X.; Peng, J.; Zhu, Y.; Dong, R.; He, J.; Xia, L.; Liu, S.; Chen, J.; Xu, Z.; et al. Proline Exacerbates Hepatic Gluconeogenesis via Paraspeckle-Dependent mRNA Retention. Nat. Metab. 2025, 7, 367–382. [Google Scholar] [CrossRef] [PubMed]
- Myllyharju, J. Prolyl 4-Hydroxylases, Key Enzymes in the Synthesis of Collagens and Regulation of the Response to Hypoxia, and Their Roles as Treatment Targets. Ann. Med. 2008, 40, 402–417. [Google Scholar] [CrossRef] [PubMed]
- Rahtu-Korpela, L.; Karsikas, S.; Hörkkö, S.; Blanco Sequeiros, R.; Lammentausta, E.; Mäkelä, K.A.; Herzig, K.-H.; Walkinshaw, G.; Kivirikko, K.I.; Myllyharju, J.; et al. HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects against Obesity and Metabolic Dysfunction. Diabetes 2014, 63, 3324–3333. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Zhang, Q.; Li, S.; Wang, S.; Zhou, F.; Zhang, H.; Chen, J. Shenhuang Liuwei Powder Alleviates Streptozotocin-Induced Diabetic Ulcers in Rats through the Inhibition of the AGE/RAGE Signaling Pathway and Promotion of Antibacterial Activity and Angiogenesis via Activation of the PI3K/Akt/eNOS/HIF-1α Pathway. Comb. Chem. High Throughput Screen. 2025, 28, 1–24. [Google Scholar] [CrossRef] [PubMed]
- Catrina, S.-B.; Zheng, X. Hypoxia and Hypoxia-Inducible Factors in Diabetes and Its Complications. Diabetologia 2021, 64, 709–716. [Google Scholar] [CrossRef] [PubMed]
- Gorres, K.L.; Raines, R.T. Prolyl 4-Hydroxylase. Crit. Rev. Biochem. Mol. Biol. 2010, 45, 106–124. [Google Scholar] [CrossRef] [PubMed]
- Pilley, S.E.; Awad, D.; Latumalea, D.; New, C.; Esparza, E.; Wang, S.; Shi, X.; Zhang, L.; Unfried, M.; Lee, J.H.; et al. A Metabolic Atlas of Mouse Aging. Cell Metab. 2026, 38, 399–418.e7. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X.; Huang, J.; Li, H.; Zhao, D.; Liu, Z.; Zhu, L.; Zhang, Z.; Peng, W. Quercetin: A Promising Therapy for Diabetic Encephalopathy through Inhibition of Hippocampal Ferroptosis. Phytomedicine 2024, 126, 154887. [Google Scholar] [CrossRef] [PubMed]
- Liang, J.; He, Y.; Huang, C.; Ji, F.; Zhou, X.; Yin, Y. The Regulation of Selenoproteins in Diabetes: A New Way to Treat Diabetes. Curr. Pharm. Des. 2024, 30, 1541–1547. [Google Scholar] [CrossRef] [PubMed]


| Overall (n = 796) | Diabetes | p-Value | ||
|---|---|---|---|---|
| No (n = 682) | Yes (n = 114) | |||
| Age, years | 69.1 (62.6, 75.1) | 69.3 (62.8, 75.3) | 68.4 (61.4, 73.3) | 0.07 |
| Sex (%) | ||||
| Male | 364 (45.7) | 319 (46.8) | 45 (39.5) | 0.18 |
| Female | 432 (54.3) | 363 (53.2) | 69 (60.5) | |
| Current smoking (%) | ||||
| No | 591 (74.2) | 499 (73.2) | 92 (80.7) | 0.11 |
| Yes | 205 (25.8) | 183 (26.8) | 22 (19.3) | |
| Drinking (%) | ||||
| No | 662 (83.2) | 561 (82.3) | 101 (88.6) | 0.12 |
| Yes | 134 (16.8) | 121 (17.7) | 13 (11.4) | |
| Dyslipidemia (%) | ||||
| No | 582 (73.1) | 520 (76.2) | 62 (54.4) | <0.001 |
| Yes | 214 (26.9) | 162 (23.8) | 52 (45.6) | |
| Hypertension (%) | ||||
| No | 205 (25.8) | 183 (26.8) | 22 (19.3) | 0.11 |
| Yes | 591 (74.2) | 499 (73.2) | 92 (80.7) | |
| BMI, kg/m2 | 23.0 (21.3, 25.8) | 23.3 (21.1, 25.5) | 24.4 (21.9, 27.0) | 0.001 |
| Physical activity, MET-h/d | 21.4 (12.9, 34.9) | 21.1 (12.9, 34.8) | 22.4 (12.6, 35.4) | 0.86 |
| Animal food intake (g/d) 1 | ||||
| Red meat intake | 25.0 (13.5, 41.0) | 24.9 (13.3, 40.4) | 27.7 (14.1, 43.0) | 0.33 |
| Poultry intake | 17.0 (7.4, 30.2) | 17.0 (7.0, 30.2) | 16.8 (9.9, 30.1) | 0.63 |
| Fish/seafood intake | 26.3 (14.0, 44.8) | 26.3 (14.2, 44.7) | 26.0 (12.9, 45.9) | 0.79 |
| Egg intake | 22.4 (12.2, 41.5) | 22.0 (12.2, 42.2) | 24.6 (12.3, 39.9) | 0.81 |
| Total | 108.3 (67.6, 167.7) | 107.9 (67.6, 165.9) | 112.8 (66.8, 193.3) | 0.33 |
| Total protein intake (g/d) 1 | 55.1 (50.1, 63.0) | 55.0 (50.3, 62.8) | 55.7 (49.6, 64.2) | 0.79 |
| Total energy intake (kcal/d) | 1872.3 (1473.0, 2247.7) | 1889.6 (1474.7, 2273.1) | 1774.0 (1444.7, 2113.1) | 0.26 |
| Antidiabetic medication use (%) | <0.001 | |||
| No | 751 (94.3) | 682 (100) | 69 (60.5) | |
| Yes | 45 (5.7) | 0 (0.0) | 45 (39.5) | |
| Self-report diabetes (%) | <0.001 | |||
| No | 645 (91.2) | 601 (100.0) | 44 (41.5) | |
| Yes | 62 (8.8) | 0 (0.0) | 62 (58.5) | |
| Fasting glucose (%) | <0.001 | |||
| <7.0 mmol/L | 700 (87.9) | 682 (100.0) | 18 (15.8) | |
| ≥7.0 mmol/L | 96 (12.1) | 0 (0.0) | 96 (84.2) | |
| eGFR, ml/min/1.73 m2 | ||||
| <60 | 716 (89.9) | 619 (90.8) | 97 (85.1) | 0.09 |
| ≥60 | 80 (10.1) | 63 (9.2) | 17 (14.9) | |
| Proline (umol/L) | 213.3 (173.7, 261.9) | 208.1 (172.4, 255.9) | 229.0 (183.3, 300.8) | 0.001 |
| 4-Hydroxyproline (umol/L) | 17.9 (12.3, 27.0) | 17.2 (12.1, 26.3) | 21.7 (14.6, 33.0) | 0.010 |
| 4-Hydroxyproline, umol/L | Quartile (Q) | p for Trend a | Continuous b | p-Value b | |||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||||
| Model 1 | Ref | 0.97 (0.51, 1.84) | 1.95 (1.10, 3.53) | 1.96 (1.09, 3.58) | 0.004 | 1.37 (1.13, 1.67) | 0.002 |
| Model 2 | Ref | 0.86 (0.44, 1.67) | 1.95 (1.08, 3.58) | 1.86 (1.01, 3.47) | 0.006 | 1.35 (1.10, 1.66) | 0.004 |
| After exclusion of individuals who used insulin (n = 8) | |||||||
| Model 1 | Ref | 0.89 (0.45, 1.74) | 2.03 (1.13, 3.72) | 1.92 (1.05, 3.56) | 0.005 | 1.37 (1.12, 1.68) | 0.002 |
| Model 2 | Ref | 0.77 (0.39, 1.54) | 1.99 (1.09, 3.70) | 1.80 (0.97, 3.43) | 0.007 | 1.35 (1.09, 1.66) | 0.005 |
| After exclusion of individuals with diabetes complications (n = 16) | |||||||
| Model 1 | Ref | 0.98 (0.49, 1.94) | 1.92 (1.04, 3.62) | 2.00 (1.08, 3.81) | 0.006 | 1.38 (1.12, 1.70) | 0.002 |
| Model 2 | Ref | 0.88 (0.43, 1.78) | 1.93 (1.03, 3.68) | 1.96 (1.03, 3.80) | 0.007 | 1.37 (1.11, 1.70) | 0.004 |
| After exclusion of individuals who use antidiabetic medication (n = 45) | |||||||
| Model 1 | Ref | 1.08 (0.47, 2.49) | 2.21 (1.07, 4.79) | 2.01 (0.95, 4.44) | 0.016 | 1.35 (1.06, 1.72) | 0.021 |
| Model 2 | Ref | 0.98 (0.42, 2.30) | 2.16 (1.03, 4.74) | 1.96 (0.90, 4.40) | 0.024 | 1.35 (1.05, 1.73) | 0.020 |
| Quartile (Q) | p for Trend a | Continuous b | p-Value b | ||||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||||
| Model 2+ red meat intake 1 | Ref | 0.86 (0.44, 1.67) | 1.95 (1.08, 3.58) | 1.86 (1.01, 3.47) | 0.006 | 1.35 (1.10, 1.66) | 0.004 |
| Model 2+ total protein intake 2 | Ref | 0.86 (0.44, 1.66) | 1.95 (1.08, 3.58) | 1.85 (1.01, 3.46) | 0.006 | 1.35 (1.10, 1.66) | 0.004 |
| Model 2+ total energy intake 3 | Ref | 0.86 (0.44, 1.67) | 1.95 (1.08, 3.58) | 1.82 (0.99, 3.40) | 0.008 | 1.34 (1.09, 1.65) | 0.005 |
| Model 2+ proline 4 | Ref | 0.8 (0.41, 1.55) | 1.78 (0.98, 3.29) | 1.51 (0.79, 2.92) | 0.040 | 1.27 (1.02, 1.58) | 0.036 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Huang, Q.; Mu, Y.; Ma, R.; Zhu, J.; Wang, X.; Wang, Q.; Huang, J.; Zuo, H.; Yu, J. Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis. Metabolites 2026, 16, 467. https://doi.org/10.3390/metabo16070467
Huang Q, Mu Y, Ma R, Zhu J, Wang X, Wang Q, Huang J, Zuo H, Yu J. Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis. Metabolites. 2026; 16(7):467. https://doi.org/10.3390/metabo16070467
Chicago/Turabian StyleHuang, Qiaoliang, Yingjun Mu, Ruirui Ma, Jiayao Zhu, Xudong Wang, Qingyao Wang, Junyao Huang, Hui Zuo, and Jinming Yu. 2026. "Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis" Metabolites 16, no. 7: 467. https://doi.org/10.3390/metabo16070467
APA StyleHuang, Q., Mu, Y., Ma, R., Zhu, J., Wang, X., Wang, Q., Huang, J., Zuo, H., & Yu, J. (2026). Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis. Metabolites, 16(7), 467. https://doi.org/10.3390/metabo16070467

